Massachusetts-based AI drug discovery company Differentiated Therapeutics has raised USD 5 million in a seed funding round financed by Curie.Bio. The proceeds will be directed toward establishing its pipeline of targeted protein degraders (TPD)-based therapeutics.
Founded in 2021, Differentiated Therapeutics develops novel therapeutics across a variety of therapeutic areas by leveraging its proprietary end-to-end drug discovery platform “Auto/dx” that integrates AI, synthetic biology, and molecular simulation. The platform enables biological discovery of novel TPD targets, biomarker stratification, and patient selection.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.